Aliases & Classifications for Myocardial Stunning

MalaCards integrated aliases for Myocardial Stunning:

Name: Myocardial Stunning 12 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9767
MeSH 44 D017682
UMLS 73 C0206146

Summaries for Myocardial Stunning

MalaCards based summary : Myocardial Stunning is related to ischemia and ventricular fibrillation, paroxysmal familial, 1, and has symptoms including asthenia, body temperature changes and cyanosis. An important gene associated with Myocardial Stunning is SLC9A1 (Solute Carrier Family 9 Member A1), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Folate Metabolism. The drugs Clopidogrel and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include heart, eye and bone, and related phenotypes are Negative genetic interaction between BLM-/- and BLM+/+ and Reduced mammosphere formation

Wikipedia : 76 In cardiology, stunned myocardium is a state when some section of the myocardium (corresponding to area... more...

Related Diseases for Myocardial Stunning

Diseases related to Myocardial Stunning via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 ischemia 31.0 EDN1 SLC9A1 SOD1
2 ventricular fibrillation, paroxysmal familial, 1 29.8 KCNJ5 SLC9A1 TNNT2
3 chronic kidney failure 29.7 AGTR1 EDN1 SOD1
4 myocardial infarction 29.0 AGTR1 EDN1 SERPINC1 TNNI3 TNNT2
5 acute myocardial infarction 28.9 AGTR1 EDN1 SERPINC1 TNNI3 TNNT2
6 arteries, anomalies of 28.8 AGTR1 EDN1 SERPINC1 TNNI3 TNNT2
7 coronary artery anomaly 28.2 AGTR1 EDN1 SLC9A1 SOD3 TNNI3 TNNT2
8 familial isolated restrictive cardiomyopathy 10.6 TNNI3 TNNT2
9 platelet aggregation, spontaneous 10.5 SERPINC1 SOD1
10 gas gangrene 10.5 TNNI3 TNNT2
11 anoxia 10.4 KCNJ5 SOD1
12 angina pectoris 10.4 EDN1 SERPINC1
13 meningococcal infection 10.3 AGTR1 SOD1
14 meningitis and encephalitis 10.3 CAT SOD1
15 hepatic vascular disease 10.3 EDN1 SERPINC1
16 familial isolated dilated cardiomyopathy 10.3 TNNI3 TNNT2
17 raynaud phenomenon 10.3 AGTR1 EDN1
18 erysipelas 10.3 CAT SOD1
19 aortic coarctation 10.2 AGTR1 EDN1
20 malignant hypertension 10.2 AGTR1 EDN1
21 renal hypertension 10.2 AGTR1 EDN1
22 intermediate coronary syndrome 10.1 SERPINC1 TNNI3 TNNT2
23 endotheliitis 10.1
24 pulmonary embolism 10.1 SERPINC1 TNNI3 TNNT2
25 familial hyperaldosteronism 10.1 AGTR1 KCNJ5
26 retinal ischemia 10.1 CAT SOD1
27 acute mountain sickness 10.1 AGTR1 EDN1
28 intermittent claudication 10.0 SERPINC1 TNNT2
29 hypertrophic cardiomyopathy 10.0
30 limb ischemia 10.0 EDN1 TNNI3
31 diabetic angiopathy 10.0 CAT EDN1
32 aging 9.9
33 cardiac arrest 9.9
34 pulmonary edema 9.9
35 aneurysm 9.9
36 hypoxia 9.9
37 cardiogenic shock 9.9
38 ischemic optic neuropathy 9.9 AGTR1 EDN1 SERPINC1
39 nonarteritic anterior ischemic optic neuropathy 9.9 AGTR1 EDN1 SERPINC1
40 stroke, ischemic 9.8
41 pulmonary hypertension 9.8
42 status epilepticus 9.8
43 epilepsy 9.8
44 cervicitis 9.8
45 cerebritis 9.8
46 coronary stenosis 9.8
47 kidney disease 9.8
48 hyperthyroidism 9.8
49 peritonitis 9.8
50 intrinsic cardiomyopathy 9.8 TNNI3 TNNT2

Graphical network of the top 20 diseases related to Myocardial Stunning:



Diseases related to Myocardial Stunning

Symptoms & Phenotypes for Myocardial Stunning

UMLS symptoms related to Myocardial Stunning:


asthenia, body temperature changes, cyanosis, edema, eye manifestations, fatigue, oral manifestations, signs and symptoms, signs and symptoms, digestive, signs and symptoms, respiratory, skin manifestations, chills, polydipsia, renal colic, hot flushes, urological manifestations, mobility limitation, prodromal symptoms, hypertriglyceridemic waist, medically unexplained symptoms

GenomeRNAi Phenotypes related to Myocardial Stunning according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Negative genetic interaction between BLM-/- and BLM+/+ GR00255-A-1 9.35 EDN1 OPRD1 SOD3 TNNI3 TNNT2
2 Reduced mammosphere formation GR00396-S 9.02 AGTR1 KCNJ5 OPRD1 SERPINC1 SLC9A1

MGI Mouse Phenotypes related to Myocardial Stunning:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.86 AGTR1 EDN1 KCNJ5 SERPINC1 SLC9A1 SOD1
2 homeostasis/metabolism MP:0005376 9.81 AGTR1 CAT EDN1 OPRD1 SERPINC1 SLC9A1
3 mortality/aging MP:0010768 9.61 AGTR1 CAT EDN1 SERPINC1 SLC9A1 SOD1
4 nervous system MP:0003631 9.17 EDN1 OPRD1 SERPINC1 SLC9A1 SOD1 TNNT2

Drugs & Therapeutics for Myocardial Stunning

Drugs for Myocardial Stunning (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
2
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
3
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
4
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
5
Ticagrelor Approved Phase 4 274693-27-5 9871419
6
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
7
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
8
Glucosamine Approved, Investigational, Nutraceutical Phase 4 3416-24-8 439213
9 Nutmeg Approved, Nutraceutical Phase 4
10
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4 13422-55-4
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
12
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
13 Simendan Investigational Phase 4 131741-08-7
14 Adrenergic Agents Phase 4
15 Neurotransmitter Agents Phase 4
16 Peripheral Nervous System Agents Phase 4,Not Applicable
17 Pharmaceutical Solutions Phase 4,Not Applicable
18 Antihypertensive Agents Phase 4,Not Applicable
19 Protective Agents Phase 4
20 Autonomic Agents Phase 4,Not Applicable
21 Calcium, Dietary Phase 4,Not Applicable
22 Chlorhexidine gluconate Phase 4
23 Atorvastatin Calcium Phase 4 134523-03-8
24 Rosuvastatin Calcium Phase 4 147098-20-2
25 Analgesics Phase 4
26 calcium channel blockers Phase 4
27 Fibrinolytic Agents Phase 4
28 Adrenergic Antagonists Phase 4
29 Adrenergic beta-1 Receptor Antagonists Phase 4
30 Adrenergic beta-Antagonists Phase 4
31 Sympatholytics Phase 4
32 Glucuronyl glucosamine glycan sulfate Phase 4
33 Cyclooxygenase Inhibitors Phase 4
34 Analgesics, Non-Narcotic Phase 4
35 Anti-Arrhythmia Agents Phase 4
36 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
37 Hypoglycemic Agents Phase 4,Not Applicable
38 Hypolipidemic Agents Phase 4
39 Anticholesteremic Agents Phase 4
40 Platelet Aggregation Inhibitors Phase 4
41 Anticoagulants Phase 4
42 Lipid Regulating Agents Phase 4
43 Anti-Inflammatory Agents Phase 4,Not Applicable
44 Antipyretics Phase 4
45 Purinergic P2 Receptor Antagonists Phase 4
46 Anti-Inflammatory Agents, Non-Steroidal Phase 4
47 Purinergic P2Y Receptor Antagonists Phase 4
48 Antirheumatic Agents Phase 4
49 Antimetabolites Phase 4
50 Sodium Channel Blockers Phase 4

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy) Enrolling by invitation NCT02767401 Phase 4 aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc
2 The Success of Opening Concurrent Chronic Total Occlusion leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease Enrolling by invitation NCT03372785 Phase 4 aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor
3 Ranolazine a Potential New Therapeutic Application Not yet recruiting NCT02687269 Phase 4 Ranolazine;Placebo
4 Intracoronary Administration of Levosimendan in Cardiac Surgery Patients Suspended NCT01500785 Phase 4 levosimendan;Vitamin B 12
5 Serial Echocardiography After Subarachnoid Hemorrhage Unknown status NCT00123695
6 Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration Completed NCT02545426 Not Applicable
7 Cardiac Sympathetic Activity in Patients With the Apical Ballooning Syndrome Completed NCT00586183 Not Applicable
8 Evaluation of Myocardial Viability by Means of Low-dose Dobutamine Gated SPECT (the DOGS Study) Completed NCT00213746
9 Exercise-induced Changes in Cardiac Function & Morphology Completed NCT01179802 Not Applicable
10 Analysis of Heart Muscle Function Following Exercise in Patients With Heart Disease Completed NCT00001528
11 Adjusting Fluid Removal Based on Blood Volume in Hemodialysis: A Randomized Study Completed NCT01988181 Not Applicable
12 Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients Recruiting NCT03539861 Not Applicable
13 Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients Recruiting NCT02145260 Not Applicable Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate);Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)
14 Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy Enrolling by invitation NCT02930265 Not Applicable Liraglutide
15 Rate of Left Ventricular Systolic Function's Recuperation After Cardiac Surgery With Extracorporeal Circulation. Not yet recruiting NCT02770183
16 Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients Not yet recruiting NCT02207153
17 EUROpean Study of Intracoronary Cooling in ST-Elevation Myocardial Infarction Not yet recruiting NCT03447834 Not Applicable
18 Steroid-induced Reduction of Surgical Stress Study Withdrawn NCT00807521 Not Applicable Dexamethasone;Placebo

Search NIH Clinical Center for Myocardial Stunning

Cochrane evidence based reviews: myocardial stunning

Genetic Tests for Myocardial Stunning

Anatomical Context for Myocardial Stunning

MalaCards organs/tissues related to Myocardial Stunning:

41
Heart, Eye, Bone, Neutrophil, Skin, Endothelial, Kidney

Publications for Myocardial Stunning

Articles related to Myocardial Stunning:

(show top 50) (show all 430)
# Title Authors Year
1
Better characterization of dipyridamole-induced myocardial stunning by systolic wall thickening. A gated perfusion SPECT study. ( 29951894 )
2018
2
Takotsubo syndrome or myocardial stunning due to spasm of a non-obstructive left anterior descending coronary artery? ( 29923102 )
2018
3
Myocardial stunning-induced left ventricular dyssynchrony on gated single-photon emission computed tomography myocardial perfusion imaging. ( 29794947 )
2018
4
Editorial commentary: Interpreting and dealing with myocardial stunning. ( 29221767 )
2017
5
Myocardial stunning by gated SPECT: An old tool reinvented in a stunning turn. ( 29139036 )
2017
6
Additional value of systolic wall thickening in myocardial stunning evaluated by stress-rest gated perfusion SPECT. ( 29119373 )
2017
7
Myocardial stunning occurs during intermittent haemodialysis for acute kidney injury. ( 28352974 )
2017
8
Current interpretation of myocardial stunning. ( 29221768 )
2017
9
Citric Acid Cycle Metabolites Predict the Severity of Myocardial Stunning and Mortality in Newborn Pigs. ( 27741040 )
2016
10
Doppler echocardiographic myocardial stunning index predicts recovery of left ventricular systolic function after primary percutaneous coronary intervention. ( 27543440 )
2016
11
Parafascicular nucleus-heart neural crosstalk: Implications for seizure-induced myocardial stunning. ( 27539366 )
2016
12
Pentobarbital-Induced Myocardial Stunning in Status Epilepticus Requiring Extracorporeal Membrane Oxygenation: A Case Report and Literature Review. ( 27529037 )
2016
13
Post-ischemic myocardial stunning was the starting point of takotsubo syndrome: Restitution is justified after falling down on. ( 26163910 )
2015
14
Hemodialysis-Induced Myocardial Stunning: A Review. ( 26290919 )
2015
15
Acute intraoperative neurogenic myocardial stunning during intracranial endoscopic fenestration and shunt revision in a pediatric patient. ( 26314948 )
2015
16
Ivabradine reduces myocardial stunning in patients with exercise-inducible ischaemia. ( 26419678 )
2015
17
Prevention of myocardial stunning during percutaneous coronary interventions: novel insights from pre-treatment with glucagon-like peptide-1. ( 25700753 )
2015
18
Murine Isolated Heart Model of Myocardial Stunning Associated with Cardioplegic Arrest. ( 26275089 )
2015
19
Reply to the letter "Post-ischemic myocardial stunning was the starting point of takotsubo syndrome: Restitution is justified after falling down on". ( 26285184 )
2015
20
CASE 0-2015 Problem-Solving in Transcatheter Aortic Valve Replacement: Cardiovascular Collapse, Myocardial Stunning, and Mitral Regurgitation. ( 26119409 )
2015
21
Rare giant T-wave inversions associated with myocardial stunning: report of 2 cases. ( 25068953 )
2014
22
Myocardial stunning after resuscitation from cardiac arrest following spinal anaesthesia. ( 24963188 )
2014
23
Isolated Pulmonary Edema without Myocardial Stunning in Brainstem Strokes. ( 26322335 )
2014
24
Seizure-Induced Myocardial Stunning: A Possible Cardiac Link to Sudden Unexpected Death In Epilepsy (SUDEP). ( 25305671 )
2014
25
Clinical characteristics of myocardial stunning in acute stroke. ( 25022725 )
2014
26
Cardiomyocyte-specific overexpression of an active form of Rac predisposes the heart to increased myocardial stunning and ischemia-reperfusion injury. ( 23161879 )
2013
27
CMR imaging for the evaluation of myocardial stunning after acute myocardial infarction: a meta-analysis of prospective trials. ( 23575990 )
2013
28
Takotsubo and Takotsubo-like syndrome: a common neurogenic myocardial stunning pathway? ( 23058349 )
2013
29
Hot shot induction and reperfusion with a specific blocker of the es-ENT1 nucleoside transporter before and after hypothermic cardioplegia abolishes myocardial stunning in acutely ischemic hearts despite metabolic derangement: hot shot drug delivery before hypothermic cardioplegia. ( 23422047 )
2013
30
Reversible T-Wave Inversions and Neurogenic Myocardial Stunning in a Patient with Recurrent Stress-Induced Cardiomyopathy. ( 24147830 )
2013
31
N-terminal Pro-B-type natriuretic peptide and its correlation to haemodialysis-induced myocardial stunning. ( 23880872 )
2013
32
Spontaneous coronary artery dissection triggered post-ischemic myocardial stunning and takotsubo syndrome: two different names for the same condition. ( 23273747 )
2013
33
Myocardial bridging, apical ballooning syndrome and myocardial stunning: shall we connect the dots? ( 23647592 )
2013
34
Milrinone and levosimendan administered after reperfusion improve myocardial stunning in swine. ( 22994851 )
2013
35
High-dose erythropoietin during cardiac resuscitation lessens postresuscitation myocardial stunning in swine. ( 23806450 )
2013
36
Inhalation of hydrogen gas protects against myocardial stunning and infarction in swine. ( 22263852 )
2012
37
Huge negative T waves reaching a depth of 36 mm below the isoelectric line on ECG associated with myocardial stunning. ( 22126257 )
2012
38
Stress cardiomyopathy: a syndrome of catecholamine-mediated myocardial stunning? ( 22297544 )
2012
39
Troponin T for the detection of dialysis-induced myocardial stunning in hemodialysis patients. ( 22822013 )
2012
40
Nitric oxide has no obligatory role in isoflurane late preconditioning against myocardial stunning. ( 23044225 )
2012
41
Pathophysiology and pathogenesis of post-resuscitation myocardial stunning. ( 21584712 )
2012
42
Postischemic myocardial stunning is superior to transient ischemic dilation for detecting multivessel coronary artery disease. ( 22185710 )
2012
43
Isoflurane late preconditioning against myocardial stunning is associated with enhanced antioxidant defenses. ( 22103751 )
2012
44
Myocardial Stunning with Hemodialysis: Clinical Challenges of the Cardiorenal Patient. ( 22851961 )
2012
45
Comparative assessment of rest and post-stress left ventricular volumes and left ventricular ejection fraction on gated myocardial perfusion imaging (MPI) and echocardiography in patients with transient ischaemic dilation on adenosine MPI: myocardial stunning or subendocardial hypoperfusion? ( 22565241 )
2012
46
Non-invasive ventilation for severe TRALI and myocardial stunning: report and literature review. ( 22869453 )
2012
47
Early detection of myocardial stunning using low-dose dobutamine magnetic resonance imaging. ( 21402349 )
2011
48
Complex I syndrome in myocardial stunning and the effect of adenosine. ( 21723387 )
2011
49
Distinct effects of acute pretreatment with lipophilic and hydrophilic statins on myocardial stunning, arrhythmias and lethal injury in the rat heart subjected to ischemia/reperfusion. ( 22106818 )
2011
50
Peritoneal dialysis is not associated with myocardial stunning. ( 20522673 )
2011

Variations for Myocardial Stunning

Expression for Myocardial Stunning

Search GEO for disease gene expression data for Myocardial Stunning.

Pathways for Myocardial Stunning

GO Terms for Myocardial Stunning

Cellular components related to Myocardial Stunning according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myofibril GO:0030016 9.32 TNNI3 TNNT2
2 T-tubule GO:0030315 9.26 KCNJ5 SLC9A1
3 troponin complex GO:0005861 9.16 TNNI3 TNNT2
4 cardiac myofibril GO:0097512 8.96 TNNI3 TNNT2
5 cardiac Troponin complex GO:1990584 8.62 TNNI3 TNNT2

Biological processes related to Myocardial Stunning according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.75 CAT EDN1 SOD3
2 response to oxidative stress GO:0006979 9.67 CAT SOD1 SOD3
3 cardiac muscle contraction GO:0060048 9.63 TNNI3 TNNT2
4 cellular response to hypoxia GO:0071456 9.63 EDN1 OPRD1 SLC9A1
5 response to activity GO:0014823 9.62 CAT EDN1
6 muscle filament sliding GO:0030049 9.62 TNNI3 TNNT2
7 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway GO:0051482 9.61 AGTR1 EDN1
8 regulation of mitochondrial membrane potential GO:0051881 9.61 OPRD1 SOD1
9 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.6 TNNI3 TNNT2
10 regulation of vasoconstriction GO:0019229 9.59 AGTR1 EDN1
11 skeletal muscle contraction GO:0003009 9.58 TNNI3 TNNT2
12 positive regulation of cardiac muscle hypertrophy GO:0010613 9.57 EDN1 SLC9A1
13 superoxide metabolic process GO:0006801 9.56 SOD1 SOD3
14 regulation of pH GO:0006885 9.55 EDN1 SLC9A1
15 regulation of muscle contraction GO:0006937 9.54 TNNI3 TNNT2
16 response to muscle stretch GO:0035994 9.52 EDN1 SLC9A1
17 response to copper ion GO:0046688 9.51 SOD1 SOD3
18 removal of superoxide radicals GO:0019430 9.48 SOD1 SOD3
19 heart contraction GO:0060047 9.43 SOD1 TNNI3
20 cellular response to oxidative stress GO:0034599 9.43 CAT SOD1 SOD3
21 response to reactive oxygen species GO:0000302 9.4 CAT SOD1
22 superoxide anion generation GO:0042554 9.37 EDN1 SOD1
23 negative regulation of ATPase activity GO:0032780 9.32 TNNI3 TNNT2
24 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.16 SLC9A1 TNNI3
25 response to ozone GO:0010193 8.96 CAT EDN1
26 regulation of sensory perception of pain GO:0051930 8.8 EDN1 OPRD1 SLC9A1

Molecular functions related to Myocardial Stunning according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase 2B binding GO:0030346 9.26 SLC9A1 SOD1
2 superoxide dismutase activity GO:0004784 9.16 SOD1 SOD3
3 troponin C binding GO:0030172 8.96 TNNI3 TNNT2
4 antioxidant activity GO:0016209 8.8 CAT SOD1 SOD3
5 protein binding GO:0005515 10.06 AGTR1 CAT EDN1 KCNJ5 OPRD1 SERPINC1

Sources for Myocardial Stunning

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....